Press Releases April 5, 2026

Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference

Neumora Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

By Marcus Reed NMRA
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
NMRA

Neumora Therapeutics, a clinical-stage biopharmaceutical company specializing in novel neuroscience therapies, announced its participation in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, with a live webcast available to investors and the public.

Key Points

  • Neumora specializes in developing novel therapeutics for brain diseases targeting underserved and prevalent conditions.
  • The company will engage investors and stakeholders through a fireside chat at a prominent healthcare conference, outlining its clinical pipeline and strategy.
  • Neumora aims to revolutionize neuroscience drug development to improve treatment outcomes and the quality of life for patients.

WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 10:15 a.m. ET.

A live webcast of the fireside chat will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

Neumora Contact:
Helen Rubinstein
617-402-5700
[email protected]


Risks

  • As a clinical-stage biopharmaceutical company, Neumora faces inherent risks including clinical trial outcomes and regulatory approvals impacting its pipeline progress.
  • The company operates in the highly competitive and volatile biotech sector, where innovation timelines and funding conditions can significantly affect valuation.
  • Market reception to their novel treatment approaches is uncertain and dependent on successful development and commercialization efforts.

More from Press Releases

Digital Realty Opens First Asia Pacific Innovation Lab in Japan to Help Accelerate AI and Hybrid Cloud Deployment Apr 7, 2026 Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy Apr 7, 2026 Digital Realty Opens NRT14 Data Center, Third Facility at NRT Campus in Japan Apr 7, 2026 Yimutian Inc. Reports Record Harvest Results at Wozhongtian AI-Enabled Demonstration Farms, Advancing Digital Agriculture Platform Expansion Apr 7, 2026 Legence Announces Pricing of Upsized Secondary Underwritten Public Offering of Class A Common Stock Apr 7, 2026